IQV — IQVIA Holdings Inc. stock price, charts and financials

QT71IQVIA Holdings Inc.

IQVIA Holdings Inc. (NYSE: IQV) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
241.58
+2.88+1.21%
OverviewShort InterestFilings
IQVQT71IQVIA Holdings Inc.·NYSE
241.58+1.21%
News
Up 1.2% — Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (zacks.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
A+1.40%$148.02NTRA-0.79%$319.56IDXX+1.61%$596.12WAT+0.86%$410.35MTD+0.52%$1436.82ILMN+1.52%$190.82DGX-0.47%$237.23LH-0.19%$318.55
Snapshot
IndexS&P 500P/E29.36EPS (ttm)8.13Insider Own3.15%Shs Outstand164.60MPerf Week1.57%
Market Cap39.29BForward P/E16.57EPS next Y14.40Insider Trans-2.30%Shs Float156.25MPerf Month14.23%
Enterprise Value53.62BPEG1.78EPS next Q3.24Inst Own-Short Float3.37%Perf Quarter33.62%
Income1.36BP/S2.31EPS this Y60.86%Inst Trans-Short Ratio3.20Perf Half Y31.91%
Sales16.98BP/B6.47EPS next Y11.10%ROA4.60%Short Interest5.26MPerf YTD5.90%
Book/sh-P/C14.16EPS next 5Y12.52%ROE21.95%52W High254.40 -5.04%Perf Year34.49%
Cash/sh-P/FCF15.04EPS past 3/5Y11.08% 40.54%ROIC8.32%52W Low156.36 54.50%Perf 3Y8.95%
Dividend Est.-EV/EBITDA15.20Sales past 3/5Y4.21% 7.50%Gross Margin26.23%Volatility3.16% 3.23%Perf 5Y-3.63%
Dividend TTM-EV/Sales3.16EPS Y/Y TTM7.61%Oper. Margin13.57%ATR (14)8.72Perf 10Y206.34%
Dividend Ex-Date-Quick Ratio0.71Sales Y/Y TTM10.24%Profit Margin8.10%RSI (14)65.59Recom2.18
Dividend Gr. 3/5Y-Current Ratio0.71EPS Q/Q12.10%SMA208.41%Beta1.16Target Price238.22
Payout0.00%Debt/Eq2.63Sales Q/Q8.74%SMA5018.98%Rel Volume0.66Prev Close238.70
Employees93,000LT Debt/Eq2.16EarningsOct 27SMA20020.47%Avg Volume1.58MPrice241.58
IPO DateMay 09, 2013Option/ShortYes / YesEPS/Sales Surpr.3.89% 1.53%Net Debt/EBITDA4.06Volume1,044,104Change1.21%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-29-26ReiteratedRobert W. Baird$252 → $287
Jul-29-26ReiteratedRBC CapitalOutperform$270 → $247
Jul-29-26ReiteratedBMO CapitalOutperform$250 → $270
Jul-13-26ReiteratedMizuhoOutperform$215 → $230
Jul-09-26ReiteratedDeutsche BankBuy$270 → $240
Jul-06-26ReiteratedHSBCBuy$210 → $240
Jul-01-26ReiteratedRobert W. Baird$230 → $249
Jun-17-26DowngradeMorgan StanleyOverweight → Equal Weight$225 → $200
Jun-03-26ReiteratedHSBCBuy$240 → $210
May-07-26ReiteratedMorgan StanleyOverweight$240 → $225
Latest News
Today
Today10:41AM
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Termzacks.com
Aug-07-26
Aug-07-2610:51AM
IQVIA Holdings (IQV) is a Top-Ranked Momentum Stock: Should You Buy?zacks.com
Aug-05-26
Aug-05-2605:46AM
First Trust Advisors LP Has $4.78 Million Stock Position in IQVIA Holdings Inc. $IQVdefenseworld.net
Aug-04-26
Aug-04-2608:15PM
IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug DiscoveryYahoo
01:36PM
Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?zacks.com
01:01PM
Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Lastzacks.com
04:13AM
Empowered Funds LLC Raises Holdings in IQVIA Holdings Inc. $IQVdefenseworld.net
Aug-03-26
Aug-03-2604:41AM
Insider Selling: IQVIA (NYSE:IQV) Insider Sells $1,245,800.00 in Stockdefenseworld.net
Aug-02-26
Aug-02-2603:52PM
An IQVIA Insider Sold Just Before the Stock Slipped. Here's What Long-Term Investors Should Knowfool.com
03:42PM
An IQVIA Insider Just Sold Over $1 Million in Stock. Here's What Long-Term Investors Should Knowfool.com
03:31PM
An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billionfool.com
Aug-01-26
Aug-01-2604:21AM
Amundi Has $148.20 Million Holdings in IQVIA Holdings Inc. $IQVdefenseworld.net
Jul-31-26
Jul-31-2610:55AM
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?fool.com
Jul-29-26
Jul-29-2609:59AM
IQVIA: A Great Business At The Wrong Price (Rating Downgrade)seekingalpha.com
Jul-28-26
Jul-28-2610:31PM
IQVIA (IQV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com
Company

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue16,98316,31015,405——————
Cost of Goods Sold Incl. D&A12,52812,02410,030——————
Gross Profit4,4554,2865,375——————
Selling, General and Administrative Excl. Other2,0581,9991,992——————
Research and Development
000——————
Other Operating Expense9201,181——————
Operating Income2,3052,2872,202——————
Interest Expense771729670——————
Unusual Expense
—————————
Non-Operating Income (Expense)7555137——————
Net Income Before Taxes1,6091,6131,669——————
Income Taxes253252296——————
Consolidated Net Income1,3751,3601,373——————
Net Income From Continuing Operations1,3561,3611,373——————
Net Income1,3751,3601,373——————
EPS (Recurring)8.137.917.57——————
EPS (Basic, Before Extraordinaries)8.137.917.57——————
EPS (Diluted)8.067.847.49——————
EBITDA3,5283,4643,453——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio29.9728.7526.24——————
Price To Sales Ratio2.382.382.31——————
Gross Margin26.2326.2834.89——————
Operating Margin13.5714.0214.29——————
Net Margin8.108.348.91——————
Shares Outstanding167172181——————
Market Capitalization40,34438,77135,568——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$263.83$228.58$193.33$158.08$122.83● Close Price0.00M6.98M13.96M20.93M27.91MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
STAUB W RICHARDSee RemarksAug 03 '26Sale232.685,5001,279,74013,312Aug 04
Patel BhavikSee RemarksJul 31 '26Sale235.271,855436,4261,348Aug 04
BOUSBIB ARISee RemarksJul 29 '26Option Exercise78.21156,20612,216,871992,147Jul 31
BOUSBIB ARISee RemarksJul 29 '26Sale245.51106,27926,092,072885,868Jul 31
Sherbet EricSee RemarksJul 29 '26Sale249.165,0001,245,80020,999Jul 31
Cherofsky KeriannSee RemarksJul 29 '26Sale245.21558136,8272,989Jul 31
BOUSBIB ARISee RemarksDec 18 '25Option Exercise59.9050,0002,995,000857,163Dec 19
BOUSBIB ARISee RemarksDec 18 '25Sale222.4336,5648,132,931820,599Dec 19
Sherbet EricSee RemarksOct 29 '25Option Exercise131.8210,0001,318,20031,108Oct 31
Sherbet EricSee RemarksOct 29 '25Sale219.704,000878,80027,108Oct 31
BOUSBIB ARISee RemarksOct 29 '25Option Exercise59.9077,5924,647,761884,755Oct 31
BOUSBIB ARISee RemarksOct 29 '25Sale220.3356,55712,461,120828,198Oct 31
Cherofsky KeriannSee RemarksJul 23 '25Sale191.53549105,1502,910Jul 25
Sherbet EricSee RemarksJul 23 '25Option Exercise97.2011,8701,153,76432,978Jul 25
Sherbet EricSee RemarksJul 23 '25Sale190.055,8001,102,29027,178Jul 25
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.